Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Breast Cancer Res

Retrieve available abstracts of 117 articles:
HTML format
Text format



Single Articles


    March 2017
  1. LI M, Tse LA, Chan WC, Kwok CH, et al
    Nighttime eating and breast cancer among Chinese women in Hong Kong.
    Breast Cancer Res. 2017;19:31.
    PubMed     Text format     Abstract available


  2. WALKER LC, Pearson JF, Wiggins GA, Giles GG, et al
    Increased genomic burden of germline copy number variants is associated with early onset breast cancer: Australian breast cancer family registry.
    Breast Cancer Res. 2017;19:30.
    PubMed     Text format     Abstract available


  3. ERIKSSON M, Czene K, Pawitan Y, Leifland K, et al
    A clinical model for identifying the short-term risk of breast cancer.
    Breast Cancer Res. 2017;19:29.
    PubMed     Text format     Abstract available


  4. XIONG J, Li J, Yang Q, Wang J, et al
    Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer.
    Breast Cancer Res. 2017;19:27.
    PubMed     Text format     Abstract available


  5. LEMLER DJ, Lynch ML, Tesfay L, Deng Z, et al
    DCYTB is a predictor of outcome in breast cancer that functions via iron-independent mechanisms.
    Breast Cancer Res. 2017;19:25.
    PubMed     Text format     Abstract available


  6. BUEHRING GC
    Response to "Lack of association between bovine leukemia virus and breast cancer in Chinese patients".
    Breast Cancer Res. 2017;19:24.
    PubMed     Text format    


  7. SHACKSHAFT L, Van Hemelrijck M, Garmo H, Malmstrom H, et al
    Circulating gamma-glutamyl transferase and development of specific breast cancer subtypes: findings from the Apolipoprotein Mortality Risk (AMORIS) cohort.
    Breast Cancer Res. 2017;19:22.
    PubMed     Text format     Abstract available


  8. BECA F, Kensler K, Glass B, Schnitt SJ, et al
    EZH2 protein expression in normal breast epithelium and risk of breast cancer: results from the Nurses' Health Studies.
    Breast Cancer Res. 2017;19:21.
    PubMed     Text format     Abstract available


    February 2017
  9. BAILUR JK, Pawelec G, Hatse S, Brouwers B, et al
    Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty.
    Breast Cancer Res. 2017;19:20.
    PubMed     Text format     Abstract available


  10. MCCULLOUGH LE, Chen J, Cho YH, Khankari NK, et al
    Modification of the association between recreational physical activity and survival after breast cancer by promoter methylation in breast cancer-related genes.
    Breast Cancer Res. 2017;19:19.
    PubMed     Text format     Abstract available


  11. MUSOLINO A, Campone M, Neven P, Denduluri N, et al
    Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.
    Breast Cancer Res. 2017;19:18.
    PubMed     Text format     Abstract available


  12. HU Z, Mao JH, Curtis C, Huang G, et al
    Erratum to: Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.
    Breast Cancer Res. 2017;19:17.
    PubMed     Text format    


  13. BIANCHINI G, Kiermaier A, Bianchi GV, Im YH, et al
    Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
    Breast Cancer Res. 2017;19:16.
    PubMed     Text format     Abstract available


  14. ZHANG X, Ren D, Guo L, Wang L, et al
    Thymosin beta 10 is a key regulator of tumorigenesis and metastasis and a novel serum marker in breast cancer.
    Breast Cancer Res. 2017;19:15.
    PubMed     Text format     Abstract available


    January 2017
  15. BLACK KZ, Nichols HB, Eng E, Rowley DL, et al
    Prevalence of preterm, low birthweight, and small for gestational age delivery after breast cancer diagnosis: a population-based study.
    Breast Cancer Res. 2017;19:11.
    PubMed     Text format     Abstract available


  16. ELLINGJORD-DALE M, Vos L, Tretli S, Hofvind S, et al
    Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
    Breast Cancer Res. 2017;19:10.
    PubMed     Text format     Abstract available


  17. MULLOOLY M, Yang HP, Falk RT, Nyante SJ, et al
    Relationship between crown-like structures and sex-steroid hormones in breast adipose tissue and serum among postmenopausal breast cancer patients.
    Breast Cancer Res. 2017;19:8.
    PubMed     Text format     Abstract available


  18. MA H, Ursin G, Xu X, Lee E, et al
    Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis.
    Breast Cancer Res. 2017;19:6.
    PubMed     Text format     Abstract available


  19. LIU CY, Tseng LM, Su JC, Chang KC, et al
    Erratum to: Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells.
    Breast Cancer Res. 2017;19:5.
    PubMed     Text format    


  20. ETHIER JL, Desautels D, Templeton A, Shah PS, et al
    Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res. 2017;19:2.
    PubMed     Text format     Abstract available


  21. GROHEUX D, Martineau A, Teixeira L, Espie M, et al
    18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis.
    Breast Cancer Res. 2017;19:3.
    PubMed     Text format     Abstract available


  22. MALKOV S, Shepherd JA, Scott CG, Tamimi RM, et al
    Erratum to: Mammographic texture and risk of breast cancer by tumor type and estrogen receptor status.
    Breast Cancer Res. 2017;19:1.
    PubMed     Text format    


    December 2016
  23. HORN-ROSS PL, Canchola AJ, Bernstein L, Neuhausen SL, et al
    Lifetime body size and estrogen-receptor-positive breast cancer risk in the California Teachers Study cohort.
    Breast Cancer Res. 2016;18:132.
    PubMed     Text format     Abstract available


  24. UEHIRO N, Sato F, Pu F, Tanaka S, et al
    Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
    Breast Cancer Res. 2016;18:129.
    PubMed     Text format     Abstract available


  25. WEN W, Shu XO, Guo X, Cai Q, et al
    Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestry.
    Breast Cancer Res. 2016;18:124.
    PubMed     Text format     Abstract available


  26. YOUNG AI, Law AM, Castillo L, Chong S, et al
    MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib.
    Breast Cancer Res. 2016;18:125.
    PubMed     Text format     Abstract available


  27. MALKOV S, Shepherd JA, Scott CG, Tamimi RM, et al
    Mammographic texture and risk of breast cancer by tumor type and estrogen receptor status.
    Breast Cancer Res. 2016;18:122.
    PubMed     Text format     Abstract available


  28. CARDWELL CR, Pottegard A, Vaes E, Garmo H, et al
    Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts.
    Breast Cancer Res. 2016;18:119.
    PubMed     Text format     Abstract available


  29. HUANG YS, Chen JL, Huang CS, Kuo SH, et al
    High mammographic breast density predicts locoregional recurrence after modified radical mastectomy for invasive breast cancer: a case-control study.
    Breast Cancer Res. 2016;18:120.
    PubMed     Text format     Abstract available


  30. SELLI C, Dixon JM, Sims AH
    Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers.
    Breast Cancer Res. 2016;18:118.
    PubMed     Text format     Abstract available


    November 2016
  31. LI LL, Xue AM, Li BX, Shen YW, et al
    Erratum to: JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI.
    Breast Cancer Res. 2016;18:114.
    PubMed     Text format    


  32. CATUCCI I, Radice P, Milne RL, Couch FJ, et al
    The PALB2 p.Leu939Trp mutation is not associated with breast cancer risk.
    Breast Cancer Res. 2016;18:111.
    PubMed     Text format    


  33. LINDSTROM S, Ablorh A, Chapman B, Gusev A, et al
    Deep targeted sequencing of 12 breast cancer susceptibility regions in 4611 women across four different ethnicities.
    Breast Cancer Res. 2016;18:109.
    PubMed     Text format     Abstract available


    October 2016
  34. ABUBAKAR M, Orr N, Daley F, Coulson P, et al
    Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.
    Breast Cancer Res. 2016;18:104.
    PubMed     Text format     Abstract available


  35. SACKEY H, Hui M, Czene K, Verkooijen H, et al
    The impact of in situ breast cancer and family history on risk of subsequent breast cancer events and mortality - a population-based study from Sweden.
    Breast Cancer Res. 2016;18:105.
    PubMed     Text format     Abstract available


  36. ROMANUS S, Neven P, Soubry A
    Extending the Developmental Origins of Health and Disease theory: does paternal diet contribute to breast cancer risk in daughters?
    Breast Cancer Res. 2016;18:103.
    PubMed     Text format     Abstract available


  37. ZHANG R, Jiang J, Sun W, Zhang J, et al
    Lack of association between bovine leukemia virus and breast cancer in Chinese patients.
    Breast Cancer Res. 2016;18:101.
    PubMed     Text format    


  38. STRAND F, Humphreys K, Cheddad A, Tornberg S, et al
    Novel mammographic image features differentiate between interval and screen-detected breast cancer: a case-case study.
    Breast Cancer Res. 2016;18:100.
    PubMed     Text format     Abstract available


  39. SKOL AD, Sasaki MM, Onel K
    The genetics of breast cancer risk in the post-genome era: thoughts on study design to move past BRCA and towards clinical relevance.
    Breast Cancer Res. 2016;18:99.
    PubMed     Text format     Abstract available


  40. MURANEN TA, Blomqvist C, Dork T, Jakubowska A, et al
    Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium.
    Breast Cancer Res. 2016;18:98.
    PubMed     Text format     Abstract available


    April 2016
  41. LUNDBERG FE, Johansson AL, Rodriguez-Wallberg K, Brand JS, et al
    Association of infertility and fertility treatment with mammographic density in a large screening-based cohort of women: a cross-sectional study.
    Breast Cancer Res. 2016;18:36.
    PubMed     Text format     Abstract available


  42. LEROY C, Ramos P, Cornille K, Bonenfant D, et al
    Activation of IGF1R/p110beta/AKT/mTOR confers resistance to alpha-specific PI3K inhibition.
    Breast Cancer Res. 2016;18:41.
    PubMed     Text format     Abstract available


  43. LOPEZ-KNOWLES E, Gao Q, Cheang MC, Morden J, et al
    Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas.
    Breast Cancer Res. 2016;18:39.
    PubMed     Text format     Abstract available


    March 2016
  44. ESBONA K, Inman D, Saha S, Jeffery J, et al
    COX-2 modulates mammary tumor progression in response to collagen density.
    Breast Cancer Res. 2016;18:35.
    PubMed     Text format     Abstract available


  45. WEIGAND A, Boos AM, Tasbihi K, Beier JP, et al
    Selective isolation and characterization of primary cells from normal breast and tumors reveal plasticity of adipose derived stem cells.
    Breast Cancer Res. 2016;18:32.
    PubMed     Text format     Abstract available


  46. TAN WJ, Cima I, Choudhury Y, Wei X, et al
    A five-gene reverse transcription-PCR assay for pre-operative classification of breast fibroepithelial lesions.
    Breast Cancer Res. 2016;18:31.
    PubMed     Text format     Abstract available


  47. SOKOL ES, Miller DH, Breggia A, Spencer KC, et al
    Growth of human breast tissues from patient cells in 3D hydrogel scaffolds.
    Breast Cancer Res. 2016;18:19.
    PubMed     Text format     Abstract available


    February 2016
  48. HOLM K, Staaf J, Lauss M, Aine M, et al
    An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells.
    Breast Cancer Res. 2016;18:27.
    PubMed     Text format     Abstract available


  49. HORNE HN, Sherman ME, Pfeiffer RM, Figueroa JD, et al
    Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast disease.
    Breast Cancer Res. 2016;18:24.
    PubMed     Text format     Abstract available


  50. GRUEL N, Fuhrmann L, Lodillinsky C, Benhamo V, et al
    LIN7A is a major determinant of cell-polarity defects in breast carcinomas.
    Breast Cancer Res. 2016;18:23.
    PubMed     Text format     Abstract available


  51. PETRIDIS C, Brook MN, Shah V, Kohut K, et al
    Genetic predisposition to ductal carcinoma in situ of the breast.
    Breast Cancer Res. 2016;18:22.
    PubMed     Text format     Abstract available


  52. KASIMIR-BAUER S, Bittner AK, Konig L, Reiter K, et al
    Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
    Breast Cancer Res. 2016;18:20.
    PubMed     Text format     Abstract available


  53. JOHNSTON RL, Wockner L, McCart Reed AE, Wiegmans A, et al
    High content screening application for cell-type specific behaviour in heterogeneous primary breast epithelial subpopulations.
    Breast Cancer Res. 2016;18:18.
    PubMed     Text format     Abstract available


  54. FINN RS, Aleshin A, Slamon DJ
    Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers.
    Breast Cancer Res. 2016;18:17.
    PubMed     Text format     Abstract available


    January 2016
  55. WARD AK, Mellor P, Smith SE, Kendall S, et al
    Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.
    Breast Cancer Res. 2016;18:12.
    PubMed     Text format     Abstract available


  56. GRAVES ML, Cipollone JA, Austin P, Bell EM, et al
    The cell surface mucin podocalyxin regulates collective breast tumor budding.
    Breast Cancer Res. 2016;18:11.
    PubMed     Text format     Abstract available


  57. DE GROOT S, Charehbili A, van Laarhoven HW, Mooyaart AL, et al
    Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).
    Breast Cancer Res. 2016;18:3.
    PubMed     Text format     Abstract available


  58. SGROI DC, Chapman JA, Badovinac-Crnjevic T, Zarella E, et al
    Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study.
    Breast Cancer Res. 2016;18:1.
    PubMed     Text format     Abstract available


  59. MATALKAH F, Martin E, Zhao H, Agazie YM, et al
    SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
    Breast Cancer Res. 2016;18:2.
    PubMed     Text format     Abstract available


  60. TANEI T, Choi DS, Rodriguez AA, Liang DH, et al
    Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells.
    Breast Cancer Res. 2016;18:6.
    PubMed     Text format     Abstract available


  61. WANG S, Liu JC, Kim D, Datti A, et al
    Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
    Breast Cancer Res. 2016;18:9.
    PubMed     Text format     Abstract available


  62. WITZEL I, Oliveira-Ferrer L, Pantel K, Muller V, et al
    Breast cancer brain metastases: biology and new clinical perspectives.
    Breast Cancer Res. 2016;18:8.
    PubMed     Text format     Abstract available


  63. POWELL E, Shao J, Yuan Y, Chen HC, et al
    p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.
    Breast Cancer Res. 2016;18:13.
    PubMed     Text format     Abstract available


  64. VERMA R, Foster RE, Horgan K, Mounsey K, et al
    Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer.
    Breast Cancer Res. 2016;18:10.
    PubMed     Text format     Abstract available


  65. XU K, Tian X, Oh SY, Movassaghi M, et al
    The fibroblast Tiam1-osteopontin pathway modulates breast cancer invasion and metastasis.
    Breast Cancer Res. 2016;18:14.
    PubMed     Text format     Abstract available


  66. SILVESTRI V, Barrowdale D, Mulligan AM, Neuhausen SL, et al
    Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.
    Breast Cancer Res. 2016;18:15.
    PubMed     Text format     Abstract available


  67. BRAUNSTEIN M, Liao L, Lyttle N, Lobo N, et al
    Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer.
    Breast Cancer Res. 2016;18:16.
    PubMed     Text format     Abstract available


  68. ALI HR, Dariush A, Provenzano E, Bardwell H, et al
    Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer.
    Breast Cancer Res. 2016;18:21.
    PubMed     Text format     Abstract available


  69. OGONY J, Choi HJ, Lui A, Cristofanilli M, et al
    Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner.
    Breast Cancer Res. 2016;18:25.
    PubMed     Text format     Abstract available


  70. BASHARI MH, Fan F, Vallet S, Sattler M, et al
    Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.
    Breast Cancer Res. 2016;18:26.
    PubMed     Text format     Abstract available


  71. BULFONI M, Gerratana L, Del Ben F, Marzinotto S, et al
    In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis.
    Breast Cancer Res. 2016;18:30.
    PubMed     Text format     Abstract available


  72. VAN LA PARRA RF, Kuerer HM
    Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials.
    Breast Cancer Res. 2016;18:28.
    PubMed     Text format     Abstract available


  73. KROP IE, Modi S, LoRusso PM, Pegram M, et al
    Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer.
    Breast Cancer Res. 2016;18:34.
    PubMed     Text format     Abstract available


  74. LIU YR, Jiang YZ, Xu XE, Yu KD, et al
    Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer.
    Breast Cancer Res. 2016;18:33.
    PubMed     Text format     Abstract available


  75. SALEM I, Alsalahi M, Chervoneva I, Aburto LD, et al
    The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells.
    Breast Cancer Res. 2016;18:37.
    PubMed     Text format     Abstract available


  76. DAS SG, Romagnoli M, Mineva ND, Barille-Nion S, et al
    miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells.
    Breast Cancer Res. 2016;18:40.
    PubMed     Text format     Abstract available


  77. ZHANG F, Dong W, Zeng W, Zhang L, et al
    Naringenin prevents TGF-beta1 secretion from breast cancer and suppresses pulmonary metastasis by inhibiting PKC activation.
    Breast Cancer Res. 2016;18:38.
    PubMed     Text format     Abstract available


  78. DUCHNOWSKA R, Peksa R, Radecka B, Mandat T, et al
    Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis.
    Breast Cancer Res. 2016;18:43.
    PubMed     Text format     Abstract available


  79. HRUSKA CB, Scott CG, Conners AL, Whaley DH, et al
    Background parenchymal uptake on molecular breast imaging as a breast cancer risk factor: a case-control study.
    Breast Cancer Res. 2016;18:42.
    PubMed     Text format     Abstract available


  80. WANG M, Klevebring D, Lindberg J, Czene K, et al
    Determining breast cancer histological grade from RNA-sequencing data.
    Breast Cancer Res. 2016;18:48.
    PubMed     Text format     Abstract available


  81. VAN LUIJT PA, Heijnsdijk EA, Fracheboud J, Overbeek LI, et al
    The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening.
    Breast Cancer Res. 2016;18:47.
    PubMed     Text format     Abstract available


  82. HINZEY A, Gaudier-Diaz MM, Lustberg MB, DeVries AC, et al
    Breast cancer and social environment: getting by with a little help from our friends.
    Breast Cancer Res. 2016;18:54.
    PubMed     Text format     Abstract available


  83. HABEL LA, Lipson JA, Achacoso N, Rothstein JH, et al
    Case-control study of mammographic density and breast cancer risk using processed digital mammograms.
    Breast Cancer Res. 2016;18:53.
    PubMed     Text format     Abstract available


  84. MORRISSEY B, Blyth K, Carter P, Chelala C, et al
    SEARCHBreast: a new online resource to make surplus material from in vivo models of breast cancer visible and accessible to researchers.
    Breast Cancer Res. 2016;18:59.
    PubMed     Text format    


  85. SIMIGDALA N, Gao Q, Pancholi S, Roberg-Larsen H, et al
    Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
    Breast Cancer Res. 2016;18:58.
    PubMed     Text format     Abstract available


  86. WEN WX, Soo JS, Kwan PY, Hong E, et al
    Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation.
    Breast Cancer Res. 2016;18:56.
    PubMed     Text format     Abstract available


  87. MA H, Xu X, Clague J, Lu Y, et al
    Recreational physical activity and risk of triple negative breast cancer in the California Teachers Study.
    Breast Cancer Res. 2016;18:62.
    PubMed     Text format     Abstract available


  88. KRISHNAN K, Baglietto L, Apicella C, Stone J, et al
    Mammographic density and risk of breast cancer by mode of detection and tumor size: a case-control study.
    Breast Cancer Res. 2016;18:63.
    PubMed     Text format     Abstract available


  89. ALLOTT EH, Geradts J, Sun X, Cohen SM, et al
    Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.
    Breast Cancer Res. 2016;18:68.
    PubMed     Text format     Abstract available


  90. FINN RS, Crown JP, Ettl J, Schmidt M, et al
    Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
    Breast Cancer Res. 2016;18:67.
    PubMed     Text format     Abstract available


  91. WILSON LE, D'Aloisio AA, Sandler DP, Taylor JA, et al
    Long-term use of calcium channel blocking drugs and breast cancer risk in a prospective cohort of US and Puerto Rican women.
    Breast Cancer Res. 2016;18:61.
    PubMed     Text format     Abstract available


  92. MIYOSHI Y, Shien T, Ogiya A, Ishida N, et al
    Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.
    Breast Cancer Res. 2016;18:73.
    PubMed     Text format     Abstract available


  93. HU Z, Mao JH, Curtis C, Huang G, et al
    Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.
    Breast Cancer Res. 2016;18:70.
    PubMed     Text format     Abstract available


  94. LANGBALLE R, Mellemkjaer L, Malone KE, Lynch CF, et al
    Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study.
    Breast Cancer Res. 2016;18:65.
    PubMed     Text format     Abstract available


  95. SCHOEMAKER MJ, Jones ME, Wright LB, Griffin J, et al
    Psychological stress, adverse life events and breast cancer incidence: a cohort investigation in 106,000 women in the United Kingdom.
    Breast Cancer Res. 2016;18:72.
    PubMed     Text format     Abstract available


  96. ZENG C, Guo X, Long J, Kuchenbaecker KB, et al
    Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus.
    Breast Cancer Res. 2016;18:64.
    PubMed     Text format     Abstract available


  97. LOANE J
    Comment on: Tan WJ, Cima I, Choudhury Y, Wei X, Lim JCT, Thicke AA, Tan MH, Tan PH. A five-gene reverse transcription-PCR assay for pre-operative classification of breast fibroepithelial lesions. Breast Cancer Research 2016;18:31.
    Breast Cancer Res. 2016;18:77.
    PubMed     Text format    


  98. FONTELLES CC, Guido LN, Rosim MP, Andrade Fde O, et al
    Paternal programming of breast cancer risk in daughters in a rat model: opposing effects of animal- and plant-based high-fat diets.
    Breast Cancer Res. 2016;18:71.
    PubMed     Text format     Abstract available


  99. NOGALES-CADENAS R, Cai Y, Lin JR, Zhang Q, et al
    MicroRNA expression and gene regulation drive breast cancer progression and metastasis in PyMT mice.
    Breast Cancer Res. 2016;18:75.
    PubMed     Text format     Abstract available


  100. WU S, Berg WA, Zuley ML, Kurland BF, et al
    Breast MRI contrast enhancement kinetics of normal parenchyma correlate with presence of breast cancer.
    Breast Cancer Res. 2016;18:76.
    PubMed     Text format     Abstract available


  101. MANI NL, Schalper KA, Hatzis C, Saglam O, et al
    Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer.
    Breast Cancer Res. 2016;18:78.
    PubMed     Text format     Abstract available


  102. BOURGEOIS-DAIGNEAULT MC, St-Germain LE, Roy DG, Pelin A, et al
    Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment.
    Breast Cancer Res. 2016;18:83.
    PubMed     Text format     Abstract available


  103. LOO CE, Rigter LS, Pengel KE, Wesseling J, et al
    Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.
    Breast Cancer Res. 2016;18:82.
    PubMed     Text format     Abstract available


  104. SETHURAMAN A, Brown M, Seagroves TN, Wu ZH, et al
    SMARCE1 regulates metastatic potential of breast cancer cells through the HIF1A/PTK2 pathway.
    Breast Cancer Res. 2016;18:81.
    PubMed     Text format     Abstract available


  105. CHOLLET-HINTON L, Anders CK, Tse CK, Bell MB, et al
    Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the Carolina Breast Cancer Study: a case-control study.
    Breast Cancer Res. 2016;18:79.
    PubMed     Text format     Abstract available


  106. PALMER JR, Gerlovin H, Bethea TN, Bertrand KA, et al
    Predicted 25-hydroxyvitamin D in relation to incidence of breast cancer in a large cohort of African American women.
    Breast Cancer Res. 2016;18:86.
    PubMed     Text format     Abstract available


  107. BLAKEMAN V, Williams JL, Meng QJ, Streuli CH, et al
    Circadian clocks and breast cancer.
    Breast Cancer Res. 2016;18:89.
    PubMed     Text format     Abstract available


  108. HANNAFON BN, Trigoso YD, Calloway CL, Zhao YD, et al
    Plasma exosome microRNAs are indicative of breast cancer.
    Breast Cancer Res. 2016;18:90.
    PubMed     Text format     Abstract available


  109. ILMER M, Mazurek N, Gilcrease MZ, Byrd JC, et al
    Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells.
    Breast Cancer Res. 2016;18:97.
    PubMed     Text format     Abstract available


  110. BUSANA MC, Eng A, Denholm R, Dowsett M, et al
    Impact of type of full-field digital image on mammographic density assessment and breast cancer risk estimation: a case-control study.
    Breast Cancer Res. 2016;18:96.
    PubMed     Text format     Abstract available


  111. BYERLY J, Halstead-Nussloch G, Ito K, Katsyv I, et al
    PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
    Breast Cancer Res. 2016;18:95.
    PubMed     Text format     Abstract available


  112. RICE MS, Bertrand KA, VanderWeele TJ, Rosner BA, et al
    Mammographic density and breast cancer risk: a mediation analysis.
    Breast Cancer Res. 2016;18:94.
    PubMed     Text format     Abstract available


    January 2015
  113. NGUYEN TL, Aung YK, Evans CF, Yoon-Ho C, et al
    Mammographic density defined by higher than conventional brightness threshold better predicts breast cancer risk for full-field digital mammograms.
    Breast Cancer Res. 2015;17:142.
    PubMed     Text format     Abstract available


  114. HOLDMAN XB, Welte T, Rajapakshe K, Pond A, et al
    Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer.
    Breast Cancer Res. 2015;17:141.
    PubMed     Text format     Abstract available


  115. MENDES D, Alves C, Afonso N, Cardoso F, et al
    The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer - a systematic review.
    Breast Cancer Res. 2015;17:140.
    PubMed     Text format     Abstract available


  116. ALOIA A, Petrova E, Tomiuk S, Bissels U, et al
    The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features.
    Breast Cancer Res. 2015;17:146.
    PubMed     Text format     Abstract available


  117. BRENTNALL AR, Harkness EF, Astley SM, Donnelly LS, et al
    Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort.
    Breast Cancer Res. 2015;17:147.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: